The impact of regorafenib on ERK and AKT phosphorylation levels has already been investigated after short-term exposure (24 h) in CRC lines, and reported data globally show a decrease compared to non-treated cells [5,23,24,25,26,27]. The gene discussed is MAPK1; the disease is colorectal carcinoma.